Panome Bio Multi-omics Laboratory Enhances Clinical Capabilities with CLIA Certification
July 29, 2025 – St. Louis, MO – Panome Bio, a leader in advanced proteomic, metabolomic and transcriptional profiling technologies, announced it has achieved Clinical Laboratory Improvement Amendments (CLIA) certification for its state-of-the-art laboratory. This significant accomplishment validates Panome Bio’s commitment to the highest standards of quality, accuracy, and reliability in clinical laboratory testing. Panome Bio stands as the most innovative and comprehensive multi-omics service provider to hold CLIA certification.
CLIA certification is critical for researchers engaged in clinical trials, who require an elevated level of quality control, stringent documentation, and regulatory reporting. The CLIA designation demonstrates that Panome’s service platform operates with the rigor and quality required for patient sample handling and clinical laboratory test development. From sample receipt to data transfer and communication, the entire Panome process meets or exceeds the requirements for the most critical and confidential projects.
“Panome Bio has always prioritized scientific and operational excellence, and we are proud to now have a formal certification of our capabilities” said Adam Richardson, Vice President of Operations at Panome Bio. ” This CLIA certification is the result of our entire team’s commitment to accuracy and reliability, and enables Panome Bio to bring our analytical excellence to clinical trials and other regulated programs.”
Panome Bio’s newly certified laboratory features mass spectrometry-based metabolomics and proteomics technology, transcriptional profiling, and bioinformatics capabilities, ensuring the highest level of precision and throughput. The CLIA certification allows Panome Bio to offer its advanced multi-omic services to a broader range of clinical partners, including pharmaceutical companies, academic research institutions, and healthcare providers.